A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)
Latest Information Update: 21 May 2025
At a glance
- Drugs Intismeran autogene (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Registrational; Therapeutic Use
- Acronyms INTerpath-001; V940-001
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 29 Oct 2024 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 22 May 2024 According to a Moderna Inc. media release, abstracts on mRNA-4157 (V940) from this trial, have been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 - June 4 in Chicago, IL.